Day two will make the case for why C-peptide should be considered as a primary endpoint for trials in new-onset T1D. We will review the evidence that links C-peptide to clinical benefits and its correlation with improvements in HbA1c. Updated analyses of the TOMI database of new-onset clinical trials will be presented and discussed. We will then shift to a focus on how a C-peptide endpoint could enable and accelerate the development of novel therapies, the impact on clinical trial design and conduct, and the context of use that could apply. The second day will end with a comprehensive panel discussion with a focus on achieving clarity and identifying actionable next steps.